Netherlands In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2015


September 30, 2009
169 Pages - SKU: GMD2501634
License type:
Table of Contents Search inside this report Related Reports
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
3 Definitions of the Markets Covered in the Report
3.1 In Vitro Diagnostics
3.2 Clinical Chemistry
3.3 Genetic Testing
3.4 Haematology
3.5 Histology And Cytology
3.6 Immuno Chemistry
3.7 Infectious Immunology
3.8 Microbiology Culture
4 Healthcare Sector Review
4.1 Healthcare Expenditure
4.2 Healthcare Infrastructure
4.3 Healthcare Policy
5 Regulation System
5.1 Medical Equipment Approval Process
5.2 Post Market Surveillance (PMS)
6 Pricing and Reimbursement
6.1 Pricing and Reimbursement in Netherlands
7 Distribution Structure
7.1 Distribution Structure in Netherlands
8 In Vitro Diagnostics In Netherlands
8.1 In Vitro Diagnostics, Netherlands, Overall Revenue ($ mn), 2000-
8.2 In Vitro Diagnostics, Netherlands, Company Share (2007-2008)
9 Clinical Chemistry In Netherlands
9.1 Clinical Chemistry Overall Revenue (2000-2015)
9.2 Clinical Chemistry Distribution Share (2007-2008)
9.3 Clinical Chemistry, Netherlands, Company Share (2007-2008)
10 Genetic Testing In Netherlands
10.1 Genetic Testing Overall Revenue (2000-2015)
10.2 Genetic Testing Distribution Share (2007-2008)
10.3 Genetic Testing, Netherlands, Company Share (2007-2008)
11 Haematology In Netherlands
11.1 Haematology Overall Revenue (2000-2015)
11.2 Haematology Distribution Share (2007-2008)
11.3 Haematology, Netherlands, Company Share (2007-2008)
12 Histology and Cytology In Netherlands
12.1 Histology and Cytology Overall Revenue (2000-2015)
12.2 Histology and Cytology Distribution Share (2007-2008)
12.3 Histology And Cytology, Netherlands, Company Share (2007-2008)
13 Immuno Chemistry In Netherlands
13.1 Immuno Chemistry Overall Revenue (2000-2015)
13.2 Immuno Chemistry Distribution Share (2007-2008)
13.3 Immuno Chemistry, Netherlands, Company Share (2007-2008)
14 Infectious Immunology In Netherlands
14.1 Infectious Immunology Overall Revenue (2000-2015)
14.2 Infectious Immunology Distribution Share (2007-2008)
14.3 Infectious Immunology, Netherlands, Company Share (2007-2008)
15 Microbiology Culture In Netherlands
15.1 Microbiology Culture Overall Revenue (2000-2015)
15.2 Microbiology Culture Distribution Share (2007-2008)
15.3 Microbiology Culture, Netherlands, Company Share (2007-2008)
16 Overview of Key Companies in Netherlands In Vitro Diagnostics Market
16.1 Ventana Medical Systems, Inc.
16.2 Sysmex Corporation
16.3 Siemens Healthcare
16.4 Qiagen N.V.
16.5 Phadia AB
16.6 Ortho-Clinical Diagnostics Inc.
16.7 OLYMPUS CORPORATION
16.8 Inverness Medical Innovations, Inc.
16.9 Hologic, Inc.
16.10 Gen-Probe Incorporated
16.11 F. Hoffmann-La Roche Ltd.
16.12 DiaSorin S.p.A
16.13 Dade Behring Holdings, Inc.
16.14 Bio-Rad Laboratories, Inc.
16.15 bioMerieux S.A.
16.16 Becton, Dickinson and Company
16.17 Beckman Coulter, Inc.
16.18 Abbott Laboratories
16.19 Euro-Diagnostica B.V.
16.20 Nordic Immunological Laboratories
16.21 Agendia BV
17 Financial Deals Landscape
17.1 Partnerships
18 Recent Developments
18.1 Strategy And Business Planning
18.2 Research And Development
18.3 Government and Public Interest
18.4 Other Significant Developments
19 Appendix
19.1 Global Markets Direct Research Methodology
19.2 Secondary Research
19.3 Primary Research
19.4 Models
19.5 Forecasts
19.6 Expert Panel Validation
19.7 Currency Conversion
19.8 Contact Us
19.9 Disclaimer
1.1 List of Tables
Table 1: Healthcare Expenditure in Netherlands, 2000 - 2007
Table 2: Doctors by Specialty in Netherlands, 2000-2006
Table 3: Hospital Wards by Type in Netherlands, 2000-2006
Table 4: In Vitro Diagnostics, Netherlands, Overall Revenue ($ mn), 2000-2015
Table 5: In Vitro Diagnostics, Netherlands, Cross-Category Analysis, 2000-2015
Table 6: In Vitro Diagnostics, Netherlands, Overall Revenue ($ mn), Historic, 2000-2008
Table 7: In Vitro Diagnostics, Netherlands, Overall Revenue ($ mn), Forecast, 2008-2015
Table 8: In Vitro Diagnostics, Netherlands, Company Share by Revenue ($ mn), 2007-2008
Table 9: Clinical Chemistry, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2008
Table 10: Clinical Chemistry, Netherlands, Revenue ($ mn) by Segment, Forecast, 2008-2015
Table 11: Clinical Chemistry Analyzers, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Table 12: Clinical Chemistry Analyzers, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Table 13: Urine Analysis, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Table 14: Urine Analysis, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Table 15: Clinical Chemistry, Netherlands, Distribution Share by Revenue ($mn), 2007-2008
Table 16: Clinical Chemistry, Netherlands, Company Share by Revenue ($ mn), 2007-2008
Table 17: Genetic Testing, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2008
Table 18: Genetic Testing, Netherlands, Revenue ($ mn) by Segment, Forecast, 2008-2015
Table 19: Genetic Testing, Netherlands, Distribution Share by Revenue ($mn), 2007-2008
Table 20: Genetic Testing, Netherlands, Company Share by Revenue ($ mn), 2007-2008
Table 21: Haematology, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2008
Table 22: Haematology, Netherlands, Revenue ($ mn) by Segment, Forecast, 2008-2015
Table 23: Haematology Reagents, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Table 24: Haematology Reagents, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Table 25: Immunohaematology, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Table 26: Immunohaematology, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Table 27: Haemostasis, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Table 28: Haemostasis, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Table 29: Haematology Rapid Tests, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Table 30: Haematology Rapid Tests, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Table 31: Haematology Cell Counters, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Table 32: Haematology Cell Counters, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Table 33: Haematology, Netherlands, Distribution Share by Revenue ($mn), 2007-2008
Table 34: Haematology, Netherlands, Company Share by Revenue ($ mn), 2007-2008
Table 35: Histology and Cytology, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2008
Table 36: Histology and Cytology, Netherlands, Revenue ($ mn) by Segment, Forecast, 2008-2015
Table 37: Histology, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Table 38: Histology, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Table 39: Histology And Cytology, Netherlands, Distribution Share by Revenue ($mn), 2007-2008
Table 40: Histology And Cytology, Netherlands, Company Share by Revenue ($ mn), 2007-2008
Table 41: Immuno Chemistry, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2008
Table 42: Immuno Chemistry, Netherlands, Revenue ($ mn) by Segment, Forecast, 2008-2015
Table 43: Disease Specific Immunochemistry, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Table 44: Disease Specific Immunochemistry, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Table 45: Drug Related Testing, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Table 46: Drug Related Testing, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Table 47: Endocrinology Tests, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Table 48: Endocrinology Tests, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Table 49: Immunochemistry Analyzers, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Table 50: Immunochemistry Analyzers, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Table 51: Immuno Chemistry, Netherlands, Distribution Share by Revenue ($mn), 2007-2008
Table 52: Immuno Chemistry, Netherlands, Company Share by Revenue ($ mn), 2007-2008
Table 53: Infectious Immunology, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2008
Table 54: Infectious Immunology, Netherlands, Revenue ($ mn) by Segment, Forecast, 2008-2015
Table 55: Infectious Immunology, Netherlands, Distribution Share by Revenue ($mn), 2007-2008
Table 56: Infectious Immunology, Netherlands, Company Share by Revenue ($ mn), 2007-2008
Table 57: Microbiology Culture, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2008
Table 58: Microbiology Culture, Netherlands, Revenue ($ mn) by Segment, Forecast, 2008-2015
Table 59: Microbiology Analyzers, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Table 60: Microbiology Analyzers, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Table 61: Microbiology Culture, Netherlands, Distribution Share by Revenue ($mn), 2007-2008
Table 62: Microbiology Culture, Netherlands, Company Share by Revenue ($ mn), 2007-2008
Table 63: Sysmex Corporation Pipeline Products by Equipment Type
Table 64: Sysmex Corporation Pipeline Products By Development Stage
Table 65: Sysmex Corporation Pipeline Products By Therapy Area
Table 66: Sysmex Corporation Pipeline Products By News Summary
Table 67: Qiagen N.V. Pipeline Products by Equipment Type
Table 68: Qiagen N.V. Pipeline Products By Development Stage
Table 69: Qiagen N.V. Pipeline Products By Therapy Area
Table 70: Qiagen N.V. Pipeline Products By News Summary
Table 71: Phadia AB Pipeline Products by Equipment Type
Table 72: Phadia AB Pipeline Products By Development Stage
Table 73: Phadia AB Pipeline Products By Therapy Area
Table 74: Phadia AB Pipeline Products By News Summary
Table 75: Ortho-Clinical Diagnostics Inc. Pipeline Products by Equipment Type
Table 76: Ortho-Clinical Diagnostics Inc. Pipeline Products By Development Stage
Table 77: Ortho-Clinical Diagnostics Inc. Pipeline Products By Therapy Area
Table 78: Inverness Medical Innovations, Inc. Pipeline Products by Equipment Type
Table 79: Inverness Medical Innovations, Inc. Pipeline Products By Development Stage
Table 80: Inverness Medical Innovations, Inc. Pipeline Products By Therapy Area
Table 81: Inverness Medical Innovations, Inc. Pipeline Products By Clinical Trials
Table 82: Inverness Medical Innovations, Inc. Pipeline Products By News Summary
Table 83: Hologic, Inc. Pipeline Products by Equipment Type
Table 84: Hologic, Inc. Pipeline Products By Development Stage
Table 85: Hologic, Inc. Pipeline Products By Therapy Area
Table 86: Hologic, Inc. Pipeline Products By Clinical Trials
Table 87: Hologic, Inc. Pipeline Products By News Summary
Table 88: Gen-Probe Incorporated Pipeline Products by Equipment Type
Table 89: Gen-Probe Incorporated Pipeline Products By Development Stage
Table 90: Gen-Probe Incorporated Pipeline Products By Therapy Area
Table 91: Gen-Probe Incorporated Pipeline Products By Clinical Trials
Table 92: Gen-Probe Incorporated Pipeline Products By News Summary
Table 93: DiaSorin S.p.A Pipeline Products by Equipment Type
Table 94: DiaSorin S.p.A Pipeline Products By Development Stage
Table 95: DiaSorin S.p.A Pipeline Products By Therapy Area
Table 96: Becton, Dickinson and Company Pipeline Products by Equipment Type
Table 97: Becton, Dickinson and Company Pipeline Products By Development Stage
Table 98: Becton, Dickinson and Company Pipeline Products By Therapy Area
Table 99: Becton, Dickinson and Company Pipeline Products By Clinical Trials
Table 100: Becton, Dickinson and Company Pipeline Products By News Summary
Table 101: Beckman Coulter, Inc. Pipeline Products by Equipment Type
Table 102: Beckman Coulter, Inc. Pipeline Products By Development Stage
Table 103: Beckman Coulter, Inc. Pipeline Products By Therapy Area
Table 104: Beckman Coulter, Inc. Pipeline Products By News Summary
Table 105: Abbott Laboratories Pipeline Products by Equipment Type
Table 106: Abbott Laboratories Pipeline Products By Development Stage
Table 107: Abbott Laboratories Pipeline Products By Therapy Area
Table 108: IVAX Diagnostics Signs Distribution Agreement With Augurix
Table 109: HandyLab Enters Into An Agreement With Qiagen
Table 110: USD to Local Currency, Average Exchange Rate 2008
1.2 List of Figures
Figure 1: Total Healthcare Expenditure in Netherlands, 2000 - 2007
Figure 2: Government and Private Healthcare Expenditure in Netherlands, 2007
Figure 3: Healthcare Financing Framework in Netherlands, 2005
Figure 4: Flowchart for Classification of Non-invasive Devices in Netherlands, 2007
Figure 5: Flowchart for Classification of Invasive Devices in Netherlands, 2007
Figure 6: Flowchart for Classification of Invasive Devices in Netherlands, 2007
Figure 7: Flowchart for Classification of Invasive Devices in Netherlands, 2007
Figure 8: Flowchart for Classification of Invasive Devices in Netherlands, 2007
Figure 9: Flowchart for Classification of Active Devices in Netherlands, 2007
Figure 10: Flowchart for Classification of Active Devices in Netherlands, 2007
Figure 11: Flowchart for Classification of Devices except Non-invasive, Invasive and Active Devices in Netherlands, 2007
Figure 12: Conformity Assessment of Class-I Medical Devices in Netherlands, 2007
Figure 13: Conformity Assessment of Class-IIa Medical Devices in Netherlands, 2007
Figure 14: Conformity Assessment of Class-IIb Medical Devices in Netherlands, 2007
Figure 15: Conformity Assessment of Class-III Medical Devices in Netherlands, 2007
Figure 16: In Vitro Diagnostics, Netherlands, Overall Revenue ($ mn), 2000-2015
Figure 17: In Vitro Diagnostics, Netherlands, Cross-Category Analysis, 2000-2015
Figure 18: In Vitro Diagnostics, Netherlands, Overall Revenue ($ mn), Historic, 2000-2008
Figure 19: In Vitro Diagnostics, Netherlands, Overall Revenue ($ mn), Forecast, 2008-2015
Figure 20: In Vitro Diagnostics, Netherlands, Company Share (%), 2008
Figure 21: Clinical Chemistry, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2008
Figure 22: Clinical Chemistry, Netherlands, Revenue ($ mn) by Segment, Forecast, 2008-2015
Figure 23: Clinical Chemistry Analyzers, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Figure 24: Clinical Chemistry Analyzers, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Figure 25: Urine Analysis, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Figure 26: Urine Analysis, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Figure 27: Clinical Chemistry, Netherlands, Company Share (%), 2008
Figure 28: Genetic Testing, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2008
Figure 29: Genetic Testing, Netherlands, Revenue ($ mn) by Segment, Forecast, 2008-2015
Figure 30: Genetic Testing, Netherlands, Company Share (%), 2008
Figure 31: Haematology, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2008
Figure 32: Haematology, Netherlands, Revenue ($ mn) by Segment, Forecast, 2008-2015
Figure 33: Haematology Reagents, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Figure 34: Haematology Reagents, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Figure 35: Immunohaematology, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Figure 36: Immunohaematology, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Figure 37: Haemostasis, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Figure 38: Haemostasis, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Figure 39: Haematology Rapid Tests, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Figure 40: Haematology Rapid Tests, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Figure 41: Haematology Cell Counters, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Figure 42: Haematology Cell Counters, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Figure 43: Haematology, Netherlands, Company Share (%), 2008
Figure 44: Histology and Cytology, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2008
Figure 45: Histology and Cytology, Netherlands, Revenue ($ mn) by Segment, Forecast, 2008-2015
Figure 46: Histology, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Figure 47: Histology, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Figure 48: Histology And Cytology, Netherlands, Company Share (%), 2008
Figure 49: Immuno Chemistry, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2008
Figure 50: Immuno Chemistry, Netherlands, Revenue ($ mn) by Segment, Forecast, 2008-2015
Figure 51: Disease Specific Immunochemistry, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Figure 52: Disease Specific Immunochemistry, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Figure 53: Drug Related Testing, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Figure 54: Drug Related Testing, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Figure 55: Endocrinology Tests, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Figure 56: Endocrinology Tests, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Figure 57: Immunochemistry Analyzers, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Figure 58: Immunochemistry Analyzers, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Figure 59: Immuno Chemistry, Netherlands, Company Share (%), 2008
Figure 60: Infectious Immunology, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2008
Figure 61: Infectious Immunology, Netherlands, Revenue ($ mn) by Segment, Forecast, 2008-2015
Figure 62: Infectious Immunology, Netherlands, Company Share (%), 2008
Figure 63: Microbiology Culture, Netherlands, Revenue ($ mn) by Segment, Historic, 2000-2008
Figure 64: Microbiology Culture, Netherlands, Revenue ($ mn) by Segment, Forecast, 2008-2015
Figure 65: Microbiology Analyzers, Netherlands, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
Figure 66: Microbiology Analyzers, Netherlands, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
Figure 67: Microbiology Culture, Netherlands, Company Share (%), 2008
Figure 68: Global Markets Direct Methodology
 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Clinical Chemistry Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!